CureMatch Articles & News
SANTA MONICA, Calif., March 24th, 2021 – Quantgene, Inc. and CureMatch, Inc. have announced a strategic partnership to combine genomic, cloud and AI technologies and improve precision treatments and long-term outcomes for patients diagnosed with cancer. Quantgene Liquid uses blood samples of cancer patients to help provide a systemic understanding of the mutational profiles of […]
Leader brings two decades of industry experience in precision medicine, pharmaceutical and translational science to focus on personalized cancer treatments SAN DIEGO, CALIFORNIA, UNITED STATES, December 15, 2020 /EINPresswire.com/ — CureMatch, Inc., a leader in precision medicine digital solutions, has expanded its leadership team naming Ally Perlina, Ph.D., as chief science officer (CSO). In this […]
Only a minority of clinical trials evaluating immunotherapeutic agents in 2019 used a biomarker to select patients for enrollment, a study found. The findings were reported at the virtual Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting & Preconference Programs (SITC 2020). Clinical trials evaluated were listed on ClinicalTrials.gov between January 1, 2019, and […]
Next-generation sequencing (NGS) has allowed the identification of novel potential targets for patients with cancer. Examples of successful matching of tumor molecular alterations to cognate drugs include: NTRK inhibitors larotrectinib and entrectinib in multiple solid tumors with NTRK fusions1,2, ROS1 inhibitors entrectinib and crizotinib in non-small cell lung cancer (NSCLC) with ROS1 alterations3,4, and the […]
PARIS and SAN DIEGO, Oct. 12, 2020 /PRNewswire/ — WeHealth™ Digital Medicine, Servier Group’s e-health business unit, and CureMatch®, a leader in digital health precision medicine today announced that they have received CE Mark approval for Bionov™, their professional-use clinical decision support software…. read more See full article here